Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 11/20 | 0.50 |
| ▸ | CCNH | P51946 | 11/20 | 0.50 |
| ▸ | MNAT1 | P51948 | 11/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.45 |
| ▸ | CDK9 | P50750 | 9/20 | 0.45 |
| ▸ | CDK2 | P24941 | 7/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.45 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.45 |
| ▸ | CCND1 | P24385 | 2/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.45 |
| ▸ | CCND3 | P30281 | 1/20 | 0.45 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.45 |
| ▸ | CCNK | O75909 | 6/20 | 0.44 |
| ▸ | CDK12 | Q9NYV4 | 6/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10225055 | 0.89 | CDK7 (0.46) | CDK7CCNHMNAT1MAPK10BRD4 | |
| SCHEMBL84414 | 0.84 | CDK1 (0.54) | CCNT1CDK9CDK2CCNE1CDK1 | |
| SCHEMBL14383122 | 0.83 | CDK4 (0.59) | BRD4CCNT1CDK9CDK2CCNE1 | |
| SCHEMBL84078 | 0.83 | CDK1 (0.56) | CDK2CCNE1CDK1CDK4CCNB1 | |
| SCHEMBL13524818 | 0.82 | BRD4 (0.52) | CDK7CCNHMNAT1MAPK10BRD4 | |
| SCHEMBL13693348 | 0.82 | BRD4 (0.52) | CDK7CCNHMNAT1MAPK10BRD4 | |
| SCHEMBL83995 | 0.81 | CDK4 (0.47) | CDK7CDK9CDK2CCNE1CDK1 | |
| SCHEMBL19477096 | 0.80 | BRD4 (0.47) | CDK7CCNHMNAT1MAPK10BRD4 | |
| SCHEMBL15185737 | 0.79 | CCNK (0.51) | CDK7CCNHMNAT1MAPK10BRD4 | |
| SCHEMBL22895721 | 0.79 | CDK7 (0.49) | CDK7CCNHMNAT1MAPK10BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | CDK7 57/4885CCNH 455/4885MNAT1 250/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | CDK7 53/4885CCNH 522/4885MNAT1 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.